Luteinised unruptured follicle syndrome: pathophysiological background and new target therapy in assisted reproductive treatments.
Andrea EtruscoGiovanni BuzzaccariniGaspare CucinellaAntonino AgrusaGiuseppe Di BuonoMarco NoventaAntonio Simone LaganàVito ChianteraGiuseppe GulloPublished in: Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology (2022)
Luteinised unruptured follicle syndrome (LUFS) is a cause of infertility consisting in the unruptured of the dominant follicle after the LH-surge. In fact, during assisted reproductive treatments (ART) clomiphene citrate and letrozole are frequently administered in order to achieve ovulation. However, considering the pathophysiology of LUFS, new possible therapy can be proposed. On this scenario, we performed a review of the literature searching for LUFS recurrency and its impact in infertility and ART. An inflammation theory has been proposed that can be fuel for further therapeutic possibilities. In particular, considering the increase in granulocytes accumulation, the granulocyte colony-stimulating factor (G-CSF) administration has been proposed as target therapy in IUI cycles hampered by LUFS. Although data are encouraging, randomised controlled trials are needed in order to confirm the efficacy of G-CSF administration for LUFS patients.
Keyphrases
- polycystic ovary syndrome
- middle cerebral artery
- end stage renal disease
- internal carotid artery
- chronic kidney disease
- ejection fraction
- newly diagnosed
- hiv infected
- type diabetes
- stem cells
- antiretroviral therapy
- peritoneal dialysis
- mesenchymal stem cells
- prognostic factors
- metabolic syndrome
- artificial intelligence
- patient reported outcomes
- peripheral blood
- bone marrow
- endovascular treatment